Explore clinical evidence addressing MRIdian’s ability to provide physicians more control over the delivery of radiation therapy to unlock new clinical applications and pursue potentially safer delivery of hypo-fractionated and escalated radiation dose regimens.
Designed speficially for radiation oncology MRIdian provides unprecedented MRI-Guided ROAR, with over 3000 treatments and 3500 on-table adapted fractions delivered world-wide. Search over 70 peer-reviewed articles and hundreds of Congress preceedings for additional scientific information.
Pancreatic cancer presents considerable radiation targeting challenges given the known limitations of conventional CT image guidance. The novel abilities provided by live MR guidance combined with daily online treatment adaptation have potentially enabled a new approach in pancreatic cancer therapy. Learn more about the multi-center, prospective, single-arm clinical trial focused on locally advanced unresectable pancreatic cancer and the opportunities to improve survival and quality of life for this deadly disease.
The Clinical Cooperative Think Tank (C2T2) was founded by ViewRay, Inc. in 2017 to:
Dana-Farber/Brigham and Women’s Cancer Center
Henry Ford Cancer Institute
Institut du Cancer de Montpellier
Institut Paoli Calmettes
Loyola Center for Cancer Care and Research at Palos Health South Campus
Moffitt Cancer Center
Miami Cancer Institute
National Cancer Center (NCC)
Orlando Health UF Health Cancer Center
Policlinico Agostino Gemelli, Universita Cattolica del Sacro Cuore, Gemelli ART
Seoul National University Hospital (SNUH)
Sylvester Comprehensive Cancer Center, UHealth – University of Miami Health System
University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center
University of Heidelberg
University of Wisconsin Carbone Cancer Center
VU University Medical Center
Washington University and Siteman Cancer Center at Barnes-Jewish Hospital
Sign up for notifications and details.